VolitionRx Limited (VNRX)
NYSEAMERICAN: VNRX · Real-Time Price · USD
0.8513
-0.0287 (-3.26%)
Jul 28, 2026, 4:00 PM EDT - Market closed
VolitionRx Revenue
VolitionRx had revenue of $985.08K in the quarter ending March 31, 2026, with 299.81% growth. This brings the company's revenue in the last twelve months to $2.47M, up 88.49% year-over-year. In the year 2025, VolitionRx had annual revenue of $1.73M with 40.04% growth.
Revenue (ttm)
$2.47M
Revenue Growth
+88.49%
P/S Ratio
2.88
Revenue / Employee
$36,807
Employees
67
Market Cap
7.09M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.73M | 493.87K | 40.04% |
| Dec 31, 2024 | 1.23M | 458.21K | 59.10% |
| Dec 31, 2023 | 775.30K | 468.91K | 153.04% |
| Dec 31, 2022 | 306.39K | 216.36K | 240.30% |
| Dec 31, 2021 | 90.04K | 76.60K | 570.25% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Trinity Biotech | 43.79M |
| Vivos Therapeutics | 19.57M |
| Picard Medical | 5.47M |
| IceCure Medical | 3.57M |
| Sintx Technologies | 1.03M |
| Co-Diagnostics | 718.17K |
| Nexalin Technology | 275.58K |
| Phaos Technology Holdings (Cayman) Limited | 147.64K |
VNRX News
- 18 days ago - VolitionRx registers to sell 3.31M shares of common stock for holders - TheFly
- 18 days ago - VolitionRx Registration statement: Registration filing - Filings
- 21 days ago - VolitionRx announces data on prognostic value of Nu.Q Cancer Assay - TheFly
- 21 days ago - VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test - PRNewsWire
- 5 weeks ago - VolitionRx resumed with a Buy at Maxim - TheFly
- 5 weeks ago - VolitionRx announces collaboration with Sysmex - TheFly
- 5 weeks ago - VolitionRx Announces Collaboration with Sysmex - PRNewsWire
- 7 weeks ago - VolitionRx Announces Pricing of $4.6 Million Public Offering - PRNewsWire